Ferring International Center SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Ferring International Center SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013475
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; Firmagon (degarelix) for prostate cancer; and Pentasa (mesalazine) for inflammatory bowel diseases. Its pipeline products encompass FE 999310 for infertility; FE 202767 for Lactation; Testavan for male hypogonadism; and Prefix for lumbar spine fusion, among others. Ferring conducts research and development on biotechnology derived medicines such as recombinant proteins and other biologics. It has production facilities in Argentina, Denmark, Germany, China, the Czech Republic, India, Scotland, Switzerland, Israel, Mexico, and a manufacturing site in the US. Ferring is headquartered at Saint-Prex, Switzerland.

Ferring International Center SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ferring International Center SA, Medical Devices Deals, 2011 to YTD 2017 10
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Ferring International Center SA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 13
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women’s Health 15
Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 16
Ferring Pharma Acquires Assets from BioSurface Engineering 17
Ferring Pharma Acquires Ddavp from Sanofi 18
Ferring International To Acquire Assets Of Al-Kindi Pharma For US$6 Million 19
Partnerships 20
LIDDS Enters into Research Agreement with Ferring Pharma 20
Ferring International and Alrise Biosystems Enter into Co-Development Agreement 21
Ferring Pharma Enters into Agreement with CD Investments 22
Ferring Pharma Enters into Partnership with ICF 23
Ferring Pharma Enters into Agreement with Intralytix 24
Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 25
Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 26
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 27
Ferring Pharma Enters into Co-Development Agreement with Roche 28
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 29
Ferring Pharma Enters Into Co-Promotion Agreement With Kyowa Hakko For Desmopressin Acetate 30
Licensing Agreements 31
Ferring International Enters into Licensing Agreement with Enteris BioPharma 31
Ferring International Enters into Licensing Agreement with IMAB 32
Ferring Pharma Enters into Licensing Agreement with Seikagaku 33
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 34
Levo Therapeutics to Enter into Licensing Agreement with Ferring Pharma 35
TxCell Enters into Licensing Agreement with Ferring International for Ovasave 36
SciGen Expands Its Licensing Agreement With Ferring And Bio-Technology General 38
Acquisition 39
Ferring Pharma Acquires Cytokine PharmaSciences And Controlled Therapeutics 39
Ferring International Center SA – Key Competitors 40
Ferring International Center SA – Key Employees 41
Ferring International Center SA – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 47
Corporate Communications 47
Oct 02, 2017: Ferring appoints Klaus Dugi as Executive Vice President and Chief Medical Officer 47
May 23, 2017: Ferring commits $10 million to March of Dimes to expand research needed to end preterm birth 48
Apr 03, 2017: Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer 49
Government and Public Interest 50
Jun 21, 2016: Ferring demonstrates commitment to R&D investment through expanded Innovation Grants Program 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Ferring International Center SA, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ferring International Center SA, Deals By Therapy Area, 2011 to YTD 2017 9
Ferring International Center SA, Medical Devices Deals, 2011 to YTD 2017 10
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 13
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 15
Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 16
Ferring Pharma Acquires Assets from BioSurface Engineering 17
Ferring Pharma Acquires Ddavp from Sanofi 18
Ferring International To Acquire Assets Of Al-Kindi Pharma For US$6 Million 19
LIDDS Enters into Research Agreement with Ferring Pharma 20
Ferring International and Alrise Biosystems Enter into Co-Development Agreement 21
Ferring Pharma Enters into Agreement with CD Investments 22
Ferring Pharma Enters into Partnership with ICF 23
Ferring Pharma Enters into Agreement with Intralytix 24
Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 25
Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 26
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 27
Ferring Pharma Enters into Co-Development Agreement with Roche 28
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 29
Ferring Pharma Enters Into Co-Promotion Agreement With Kyowa Hakko For Desmopressin Acetate 30
Ferring International Enters into Licensing Agreement with Enteris BioPharma 31
Ferring International Enters into Licensing Agreement with IMAB 32
Ferring Pharma Enters into Licensing Agreement with Seikagaku 33
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 34
Levo Therapeutics to Enter into Licensing Agreement with Ferring Pharma 35
TxCell Enters into Licensing Agreement with Ferring International for Ovasave 36
SciGen Expands Its Licensing Agreement With Ferring And Bio-Technology General 38
Ferring Pharma Acquires Cytokine PharmaSciences And Controlled Therapeutics 39
Ferring International Center SA, Key Competitors 40
Ferring International Center SA, Key Employees 41
Ferring International Center SA, Other Locations 43
Ferring International Center SA, Subsidiaries 43

★海外企業調査レポート[Ferring International Center SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Freehold Royalties Ltd (FRU):企業の財務・戦略的SWOT分析
    Summary Freehold Royalties Ltd (Freehold Royalties), formerly Freehold Royalty Trust is an oil and gas company that offers oil and gas operation and financial performance. Its oil and gas assets generate income from natural gas, crude oil, natural gas liquids and potash deposits. It provides horizon …
  • PetSmart Inc:企業の戦略・SWOT・財務分析
    PetSmart Inc - Strategy, SWOT and Corporate Finance Report Summary PetSmart Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Ribomic Inc (4591):製薬・医療:M&Aディール及び事業提携情報
    Summary Ribomic Inc (Ribomic), a subsidiary of Otsuka Pharmaceutical Co Ltd, is a biopharmaceutical venture company. The company develops molecular targeted pharmaceutical drugs using RNA aptamers. Its technology includes RiboART system a platform technology to treat therapeutic aptamers. Ribomic’s …
  • Ghella SpA:企業の戦略・SWOT・財務情報
    Ghella SpA - Strategy, SWOT and Corporate Finance Report Summary Ghella SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • TenCate Advanced Armour:企業の戦略・SWOT・財務情報
    TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report Summary TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Marriott International Inc:企業のM&A・事業提携・投資動向
    Marriott International Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Marriott International Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Medikit Co Ltd (7749):企業の製品パイプライン分析
    Summary Medikit Co Ltd (Medikit) is a medical equipment provider that offers vascular devices. The company offers IV catheter, hemodialysis and intervention products. Its products include supercath Z3V, supercath 5 safety IV catheter, supercath AZ, supercath CLS, i-works, seiha, parent plus, parent …
  • Origin Energy Limited:企業の戦略・SWOT・財務情報
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Orascom Development Egypt Sae:企業の戦略・SWOT・財務分析
    Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report Summary Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Chesapeake Lodging Trust:企業のM&A・事業提携・投資動向
    Chesapeake Lodging Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chesapeake Lodging Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • China Gas Holdings Ltd (384):企業の財務・戦略的SWOT分析
    China Gas Holdings Ltd (384) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Public Joint-Stock Company Commercial Bank Privatbank
    Public Joint-Stock Company Commercial Bank Privatbank - Strategy, SWOT and Corporate Finance Report Summary Public Joint-Stock Company Commercial Bank Privatbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • JPMorgan Chase & Co (JPM):企業の財務・戦略的SWOT分析
    JPMorgan Chase & Co (JPM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Yara International ASA:企業の戦略・SWOT・財務分析
    Yara International ASA - Strategy, SWOT and Corporate Finance Report Summary Yara International ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Pakistan Refinery Ltd (PRL):企業の財務・戦略的SWOT分析
    Pakistan Refinery Ltd (PRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • DiaGenic ASA (NEL):医療機器:M&Aディール及び事業提携情報
    Summary DiaGenic ASA (DiaGenic) is a medical device company that develops and markets blood based biomarkers for early detection of Alzheimer’s disease. The company offers MCItect, ADtect and AMYtect products. Its ADtect is a blood test that helps distinguish mild to moderate range AD from the absen …
  • Phagelux Inc-製薬・医療分野:企業M&A・提携分析
    Summary Phagelux Inc (Phagelux) is an anti-infectives company that provides antibacterial products and solutions. The company uses phage lysis enzymes and biological agents for the treatment of antibiotic resistant bacteria and related diseases in human beings and crops. Its product portfolio includ …
  • Malayan Banking Berhad:企業のM&A・事業提携・投資動向
    Malayan Banking Berhad - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Malayan Banking Berhad Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Ego Pharmaceuticals Pty Ltd:企業の戦略的SWOT分析
    Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Saudi Arabian Mining Co:戦略・SWOT・企業財務分析
    Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report Summary Saudi Arabian Mining Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆